Updates of Colorectal Cancer Treatment

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 365

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ISMOH18_019

تاریخ نمایه سازی: 8 بهمن 1398

چکیده مقاله:

Colorectal cancer is the third most common cancer in men and the second in women worldwild and global incidenceis estimated at 1.4 million cases annually,with 694,000 deaths.There have been substantial advances in the treatment of metastatic colorectal cancer over the past 15 years and these advances have led to an improvement in survival from 12 months with fluorouracil monotherapy to more than 3 years in selected studies.Over the last decade , tremendous progress has been made in both our biologic underestanding of CRC and our molecular testing approaches.In fact the era of molecularly subsetting mCRC was initiated in 2008 , with two publications demonstrating the negative predictive impact of KRAS exon 2 mutations for the anti-EGFR agents Cetuximab and Panitumumab.Now we know that , the molecular characteristics of mCRC and identification of specific mutations can serve as predictive and prognostic indicators of disease and response to targeted therapies.These biomarkers can serve as critical tools in personalizing therapy to ensure the best outcomes.Already we hope thatadditional improvements in the survival of patients with mCRC will be made possible with the identification of new predictive molecular biomarkers and their evaluation using rational and innovative clinical trials

نویسندگان